Ovid Therapeutics Inc. ( OVID ) NASDAQ Global Select

Cena: 1.04 ( 8.67% )

Aktualizacja 08-22 21:58
NASDAQ Global Select
Branża: Biotechnology
Finanse
Rachunek zysków i strat
Bilans
Przepływy pieniężne
Prognozy
Statystyki
Dywidendy
Rekomendacje
Modele wyceny
Wskaźniki
Analiza techniczna

Notowania:

Opis firmy:

Ovid Therapeutics Inc., firma biofarmaceutyczna, rozwija wpływowe leki dla pacjentów i rodzin z zaburzeniami neurologicznymi w Stanach Zjednoczonych. Firma opracowuje OV101, kandydata na leki, który jest w badaniach klinicznych fazy 2A w leczeniu zespołu kruchego X; OV329, inhibitor aminotransferazy GABA do leczenia napadów związanych z kompleksem stwardnienia guzowatego i skurczami infantylnymi; i OV350, mała cząsteczka do leczenia padaczek. Rozwija także OV882, krótką terapię genową RNA do włosów w leczeniu zespołu Angelmana; i OV815 do leczenia zaburzenia neurologicznego związanego z kinezyną białek związanych z białkami. Firma ma umowy o licencje i współpracy z Healx, AstraZeneca AB, H. Lundbeck A/S i Northwestern University, a także Marinus Pharmaceuticals, Inc. Firma została zarejestrowana w 2014 roku i ma siedzibę w Nowym Jorku w Nowym Jorku.

Informacje o spółce:
Sektor: Zdrowie
Branża: Biotechnology
Zatrudnienie: 25
Giełda: NASDAQ Global Select
Ilość akcji w obrocie: 82.9246
Ilość akcji: Brak danych
Debiut giełdowy: 2017-05-05
WWW: https://www.ovidrx.com
CEO: Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D.
Adres: 1460 Broadway
Siedziba: 10036 New York
ISIN: US6904691010
Wskaźniki finansowe
Kapitalizacja (USD) 73 953 880
Aktywa: 102 654 000
Cena: 1.04
Wskaźnik Altman Z-Score: -3.7
Słaby (wysokie ryzyko bankructwa)
Dywidenda: 0
P/E: -1.9
Ilość akcji w obrocie: 83%
Średni wolumen: 1 848 827
Ilość akcji 71 109 500
Wskaźniki finansowe
Przychody TTM 631 562
Zobowiązania: 26 364 000
Przedział 52 tyg.: 0.243 - 1.47
Piotroski F-Score: 1
Słaby (niska jakość finansowa)
EPS: -0.5
P/E branży: 28.3
Beta: 0.41
Raport okresowy: 2025-11-11
WWW: https://www.ovidrx.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. Jeffrey A. Rona Chief Business and Financial Officer 761 235 1968
Dr. Dirk Haasner Senior Vice President of Global Manufacturing & CMC QA 416 952 1965
Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D. President, Chief Executive Officer & Chairman 1 030 026 1953
Ms. Meg Alexander Chief Strategy Officer 0 0
Mr. Tom Parry Vice President of Research and Early Development 0 0
Dr. Julia Tsai Ph.D. Senior Vice President of Clinical Development 0 1975
Dr. Toshiya Nishi D.V.M. Head of Epilepsy Research 0 0
Mr. Zhong Zhong Ph.D. Chief Scientific Officer 0 0
Lista ETF z ekspozycją na akcje Ovid Therapeutics Inc.
Symbol ETF Ilość akcji Wartość
VTI 1 792 791 591 441
Wiadomości dla Ovid Therapeutics Inc.
Tytuł Treść Źródło Aktualizacja Link
Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates Ovid Therapeutics (OVID) came out with a quarterly loss of $0.14 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.17 per share a year ago. zacks.com 2025-05-13 14:15:56 Czytaj oryginał (ang.)
Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results Topline pharmacodynamic biomarker, safety and tolerability results from a Phase 1 study of OV329 are on track to readout in Q3 2025 Ovid's first program in its KCC2 direct activator library, OV350, has been dosed in a Phase 1 study in Q1 2025; safety and tolerability results expected before year-end Cash, cash equivalents and marketable securities of $43.0 million as of March 31, 2025 are expected to support currently planned operations and development programs into the 2H of 2026 NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today reported business updates and financial results for the first quarter ended March 31, 2025. “We're off to a strong start across our pipeline and programs in what will be a defining year for Ovid,” said Dr. Jeremy Levin, D.Phil. globenewswire.com 2025-05-13 12:00:00 Czytaj oryginał (ang.)
Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 Release Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2025-05-06 15:05:33 Czytaj oryginał (ang.)
Ovid Therapeutics (OVID) Reports Q4 Loss, Lags Revenue Estimates Ovid Therapeutics (OVID) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.22 per share a year ago. zacks.com 2025-03-11 12:10:24 Czytaj oryginał (ang.)
Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results Stelios Papadopolous, Ph.D., a pioneering leader in biotech, appointed to Board of Directors; two industry veterans joined management team as Ovid prepares to take OV329 into patient trials and move its first KCC2 direct activator into the clinic Topline results from Phase 1 study of OV329 expected in Q3 2025, which will include biomarkers that measure clinical effect and target engagement, safety, and tolerability OV350, Ovid's first program in its KCC2 direct activator library, initiated a first-in-human study in Q1 2025 Cash, cash equivalents and marketable securities of $53.1 million as of December 31, 2024, are expected to support operations and development programs into the second half of 2026 NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today reported business updates and financial results for the fourth quarter and year ended December 31, 2024. globenewswire.com 2025-03-11 10:00:00 Czytaj oryginał (ang.)
Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need, today announced the appointment of Stelios Papadopoulos, Ph.D. to its Board of Directors. globenewswire.com 2025-03-03 10:00:00 Czytaj oryginał (ang.)
Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that Meg Alexander, President and Chief Operating Officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 3:10 p.m. ET in Boston, Massachusetts. globenewswire.com 2025-02-27 10:00:00 Czytaj oryginał (ang.)
Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that management will participate in a virtual presentation at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12, 2025, at 4:00 p.m. ET. globenewswire.com 2025-02-05 10:00:00 Czytaj oryginał (ang.)
Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue Estimates Ovid Therapeutics (OVID) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.16 per share a year ago. zacks.com 2024-11-12 12:31:28 Czytaj oryginał (ang.)
Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today announced the promotion of Meg Alexander to President and Chief Operating Officer (COO). Alexander will work in collaboration with Ovid's leadership team to advance Ovid's development pipeline of potential disease-halting neurotherapeutics and define and execute its go-forward strategy. globenewswire.com 2024-09-11 12:00:00 Czytaj oryginał (ang.)
Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why Ovid Therapeutics (OVID) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com 2024-08-20 17:00:22 Czytaj oryginał (ang.)
Shareholders In Ovid Therapeutics Inc Invited To Participate In Fraud Investigation With The Schall Law Firm LOS ANGELES, CA / ACCESSWIRE / August 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ:OVID) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com 2024-08-19 15:00:00 Czytaj oryginał (ang.)
Ovid Therapeutics Inc Investors Encouraged To Join Fraud Investigation With Schall Law Firm LOS ANGELES, CA / ACCESSWIRE / August 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ:OVID) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com 2024-08-18 15:00:00 Czytaj oryginał (ang.)
Ovid Therapeutics Inc Shareholders Eligible To Participate In Fraud Investigation With Schall Law Firm LOS ANGELES, CA / ACCESSWIRE / August 17, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ:OVID) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com 2024-08-17 15:00:00 Czytaj oryginał (ang.)
Ovid Therapeutics Inc Investors Invited To Join In Fraud Investigation With Schall Law Firm LOS ANGELES, CA / ACCESSWIRE / August 16, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ:OVID) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com 2024-08-16 15:00:00 Czytaj oryginał (ang.)
Ovid Therapeutics Inc Shareholders Encouraged To Join Fraud Investigation With Schall Law Firm LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ: OVID ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com 2024-08-15 15:00:00 Czytaj oryginał (ang.)
Ovid Therapeutics Inc Shareholders Invited To Join Fraud Investigation With Schall Law Firm The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ: OVID ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com 2024-08-15 02:30:00 Czytaj oryginał (ang.)
Ovid Therapeutics Inc Investors Welcome To Participate In Fraud Investigation With Schall Law Firm LOS ANGELES, CA / ACCESSWIRE / August 14, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ: OVID ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com 2024-08-14 05:15:00 Czytaj oryginał (ang.)
Ovid Therapeutics (OVID) Q2 Earnings and Revenues Surpass Estimates Ovid Therapeutics (OVID) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of a loss of $0.22 per share. This compares to loss of $0.18 per share a year ago. zacks.com 2024-08-13 14:10:22 Czytaj oryginał (ang.)
Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today reported business updates and financial results for the second quarter ended June 30, 2024. globenewswire.com 2024-08-13 12:00:00 Czytaj oryginał (ang.)
Ovid Therapeutics Inc Investors Invited To Join Fraud Investigation With Schall Law Firm LOS ANGELES, CA / ACCESSWIRE / August 12, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ: OVID ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com 2024-08-13 03:55:00 Czytaj oryginał (ang.)
Investors Of Ovid Therapeutics Inc Can Participate In Fraud Investigation With The Schall Law Firm LOS ANGELES, CA / ACCESSWIRE / August 9, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ: OVID ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com 2024-08-10 01:15:00 Czytaj oryginał (ang.)
Investors Of Ovid Therapeutics Inc Eligible To Join Fraud Investigation With The Schall Law Firm LOS ANGELES, CA / ACCESSWIRE / August 8, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ: OVID ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com 2024-08-08 20:00:00 Czytaj oryginał (ang.)
Investors Of Ovid Therapeutics Inc Can Join Fraud Investigation With The Schall Law Firm The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ: OVID ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com 2024-08-08 03:30:00 Czytaj oryginał (ang.)
Ovid Therapeutics Inc Investors Can Participate In Fraud Investigation With The Schall Law Firm LOS ANGELES, CA / ACCESSWIRE / August 6, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ: OVID ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com 2024-08-06 20:00:00 Czytaj oryginał (ang.)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVID NEW YORK, Aug. 03, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ovid Therapeutics Inc. (“Ovid” or the “Company”) (NASDAQ: OVID). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com  or 646-581-9980, ext. 7980. globenewswire.com 2024-08-03 20:18:00 Czytaj oryginał (ang.)
OVID Investors Have Opportunity to Join Ovid Therapeutics Inc. Fraud Investigation with the Schall Law Firm LOS ANGELES , Aug. 2, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ: OVID) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. prnewswire.com 2024-08-02 14:00:00 Czytaj oryginał (ang.)
OVID Investors Have Opportunity to Join Ovid Therapeutics Inc. Fraud Investigation with the Schall Law Firm LOS ANGELES--(BUSINESS WIRE)--OVID Investors Have Opportunity to Join Ovid Therapeutics Inc. Fraud Investigation with the Schall Law Firm. businesswire.com 2024-08-01 23:56:00 Czytaj oryginał (ang.)